Sequestration of gamma-aminobutyric acidA receptors on clathrin-coated vesicles during chronic benzodiazepine administration in vivo.
Chronic administration of benzodiazepine agonists produces behavioral tolerance. For induction of tolerance, the use-dependent down-regulation of gamma-aminobutyric acidA (GABA[A])/ benzodiazepine receptors is a potential cellular mechanism. We previously identified GABA(A) receptors on clathrin-coated vesicles from rat brain, suggesting that surface receptors can be internalized via endocytosis. To examine a role for coated vesicles in GABA(A) receptor down-regulation in vivo, fractions were obtained from mouse brain microsomes through density centrifugation and treatment with 0.1% Triton X-100. This coated vesicle preparation was enriched in clathrin subunits and clathrin light-chain kinase and had twice the level of [3H]flunitrazepam binding as did vesicles not exposed to Triton. Adult mice were treated with lorazepam (2 mg/kg/day) for 7 days via osmotic minipump, achieving a serum level of 103 +/- 8.9 ng/ml. The level of flunitrazepam bound to coated vesicles was increased by 83 +/- 13% in the lorazepam-treated mice compared with vehicle-treated controls. The Bmax value for [3H]flunitrazepam binding to synaptic membranes from lorazepam-treated animals was 33 +/- 4% lower than that of controls. The amount of GABA(A) receptor alpha-1 subunits, as quantified by Western blotting, followed a similar pattern. Relative to controls, immunoreactivity for alpha-1 subunits in coated vesicles from lorazepam-treated mice was increased by 60.0 +/- 10.3%, whereas that in synaptic membranes declined by 12 +/- 6%. These results indicate that lorazepam-dependent GABA(A) receptor sequestration occurs in mouse brain. Furthermore, it is suggested that this sequestration may play a role in GABA(A) receptor down-regulation in vivo.
Tehrani
M H
MH
Verna and Marrs McLean Department of Biochemistry, Baylor College of Medicine, Houston, Texas 77030, USA.
Barnes
E M
EM
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D001921:Brain / Q000378:metabolism; D002966:Clathrin / Q000494:pharmacology*; D005445:Flunitrazepam / Q000378:metabolism; D008140:Lorazepam / Q000494:pharmacology*; D051379:Mice; D008810:Mice, Inbred C57BL; D008970:Molecular Weight; D011963:Receptors, GABA-A / Q000032:analysis / Q000187:drug effects* / Q000378:metabolism
D014151:Anti-Anxiety Agents; D002966:Clathrin; D011963:Receptors, GABA-A; D005445:Flunitrazepam; D008140:Lorazepam